Community-Acquired Bacterial Pneumonia Global Clinical Trials Review, H1, 2017

2017-06-30
Price :
Published : Jun-2017
No. of Pages : 96
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Report Guidance 6
GlobalData Clinical Trials Report Coverage 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
Top Five Countries Contributing to Clinical Trials in Europe 13
Top Countries Contributing to Clinical Trials in North America 14
Top Countries Contributing to Clinical Trials in Middle East and Africa 15
Top Five Countries Contributing to Clinical Trials in Central and South America 16
Clinical Trials by G7 Countries: Proportion of Community-Acquired Bacterial Pneumonia to Infectious Disease Clinical Trials 17
Clinical Trials by Phase in G7 Countries 19
Clinical Trials in G7 Countries by Trial Status 20
Clinical Trials by E7 Countries: Proportion of Community-Acquired Bacterial Pneumonia to Infectious Disease Clinical Trials 21
Clinical Trials by Phase in E7 Countries 23
Clinical Trials in E7 Countries by Trial Status 24
Clinical Trials by Phase 25
In Progress Trials by Phase 26
Clinical Trials by Trial Status 27
Clinical Trials by End Point Status 29
Subjects Recruited Over a Period of Time 30
Clinical Trials by Sponsor Type 31
Prominent Sponsors 32
Top Companies Participating in Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials 34
Prominent Drugs 36
Latest Clinical Trials News on Community-Acquired Bacterial Pneumonia 38
Jun 05, 2017: Nabriva Therapeutics Announces Webcast of Analyst & Investor Day on June 19, 2017 38
Jun 02, 2017: Nabriva Therapeutics to present data at ASM Microbe supporting ongoing Phase 3 clinical development program for lefamulin 38
Jun 02, 2017: Eight Presentations at ASM Microbe Include Late Breaker From Cempra's Phase 3 Fusidic Acid Study and Solithromycin Data on Gonorrhea and Otitis Media 38
Apr 25, 2017: Omadacycline Concentrations Exceed Tigecycline Levels in Lungs and Epithelial Lining Fluid According to Pharmacokinetic/Pharmacodynamic Data 39
Apr 21, 2017: Cempra Presents Data at ECCMID Highlighting Need for New CABP Therapies and Activity of Solithromycin in Key Population Groups 40
Apr 13, 2017: Nabriva Therapeutics to present data at ECCMID supporting ongoing Phase 3 clinical development program for lefamulin 40
Apr 11, 2017: Nabriva Therapeutics Announces Enrollment Completion for LEAP 1, a Phase 3 Clinical Trial Evaluating Lefamulin in Community-Acquired Bacterial Pneumonia 41
Clinical Trial Profile Snapshots 42
Appendix 94
Abbreviations 94
Definitions 94
Research Methodology 95
Secondary Research 95
About GlobalData 96
Contact Us 96
Source 96

List of Tables
Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials by Region, 2017* 8
Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 10
Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 12
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 13
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, North America, Top Countries, 2017* 14
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 15
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 16
Proportion of Community-Acquired Bacterial Pneumonia to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 18
Community-Acquired Bacterial Pneumonia Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
Community-Acquired Bacterial Pneumonia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20
Proportion of Community-Acquired Bacterial Pneumonia to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 22
Community-Acquired Bacterial Pneumonia Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 23
Community-Acquired Bacterial Pneumonia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 24
Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials by Phase, 2017* 25
Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 26
Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials by Trial Status, 2017* 28
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, by End Point Status, 2017* 29
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 30
Community-Acquired Bacterial Pneumonia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 31
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 33
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 35
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 37

List of Figures
Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials by Region (%), 2017* 8
Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 12
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 13
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 14
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 15
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 16
Proportion of Community-Acquired Bacterial Pneumonia to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 17
Community-Acquired Bacterial Pneumonia Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
Community-Acquired Bacterial Pneumonia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20
Proportion of Community-Acquired Bacterial Pneumonia to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 21
Community-Acquired Bacterial Pneumonia Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 23
Community-Acquired Bacterial Pneumonia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 24
Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials by Phase (%), 2017* 25
Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 26
Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials by Trial Status, 2017* 27
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, by End Point Status, 2017* 29
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 30
Community-Acquired Bacterial Pneumonia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 31
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 32
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 34
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 36
GlobalData Methodology 95
Filed in: Pharmaceutical
Publisher : GlobalData